Factor XIII Val34Leu polymorphism and risk of recurrent pregnancy loss in Iranian population: a case control study

Abstract

BACKGROUND: Recurrent pregnancy loss (RPL) is a heterogeneous condition and thrombophilias have been considered as a probable cause.

OBJECTIVE: The aim of this study was to investigate the prevalence of the coagulation factor XIII Val34Leu polymorphism among women with unexplained RPL.

METHODS: A total of 140 women with a history of unexplained RPL and 100 age-matched healthy fertile women were recruited. The presence of FXIII Val34Leu polymorphism among the cases and controls was investigated using PCR-RFLP method.

RESULTS: Genotype analyses of the subjects revealed that the patients had a significantly higher prevalence of V/L and L/L than the controls (P<0.05): 33.5% vs. 15%, and 9.2% vs. 2%, respectively.

CONCLUSION: These results indicate a significant association between FXIII Val34Leu polymorphism and unexplained RPL in the Iranian patient.

Keywords

factor XIII / Iranian population / recurrent pregnancy loss / Val34Leu polymorphism

References

[1] Aarabi M, Memariani T, Arefi S, Aarabi M, Hantoosh Zadeh S, Akhondi M A, Modarressi M H (2011). Polymorphisms of plasminogen activator inhibitor-1, angiotensin converting enzyme and coagulation factor XIII genes in patients with recurrent spontaneous abortion. J Matern Fetal Neonatal Med, 24(3): 545–548

[2] Ariëns R A, Philippou H, Nagaswami C, Weisel J W, Lane D A, Grant P J (2000). The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure. Blood, 96(3): 988–995

[3] Bagheri M, Rad I A, Omrani M D, Nanbaksh F (2011). The Val34Leu genetic variation in the A subunit of coagulation factor XIII in recurrent spontaneous abortion. Syst Biol Reprod Med, 57(5): 261–264

[4] Bagoly Z, Koncz Z, Hársfalvi J, Muszbek L (2012). Factor XIII, clot structure, thrombosis. Thromb Res, 129(3): 382–387

[5] Balogh I, Szôke G, Kárpáti L, Wartiovaara U, Katona E, Komáromi I, Haramura G, Pfliegler G, Mikkola H, Muszbek L (2000). Val34Leu polymorphism of plasma factor XIII: biochemistry and epidemiology in familial thrombophilia. Blood, 96(7): 2479–2486

[6] Barbosa H C, Carvalho E C, Barini R, Siqueira L H, Costa D S, Annichino-Bizzacchi J M (2004). Tyr204Phe and Val34Leu polymorphisms in two Brazilian ethnic groups and in patients with recurrent miscarriages. Fertil Steril, 82(5): 1455–1457

[7] Brenner B (2002). Thrombophilia and pregnancy loss. Thromb Res, 108(4): 197–202

[8] Calderwood C J, Thanoon O I (2009). Thromboembolism and thrombophilia in pregnancy. Obstetrics, Gynaecol Reprod Med, 19(12): 339–343

[9] Catto A J, Kohler H P, Coore J, Mansfield M W, Stickland M H, Grant P J (1999). Association of a common polymorphism in the factor XIII gene with venous thrombosis. Blood, 93(3): 906–908

[10] Coulam C B, Jeyendran R S, Fishel L A, Roussev R (2006). Multiple thrombophilic gene mutations rather than specific gene mutations are risk factors for recurrent miscarriage. Am J Reprod Immunol, 55(5): 360–368

[11] de Jong P G, Goddijn M, Middeldorp S (2011). Testing for inherited thrombophilia in recurrent miscarriage. Semin Reprod Med, 29(6): 540–547

[12] de Lange M, Andrew T, Snieder H, Ge D, Futers T S, Standeven K, Spector T D, Grant P J, Ariëns R A (2006). Joint linkage and association of six single-nucleotide polymorphisms in the factor XIII-A subunit gene point to V34L as the main functional locus. Arterioscler Thromb Vasc Biol, 26(8): 1914–1919

[13] Diz-Kucukkaya R, Hancer V S, Inanc M, Nalcaci M, Pekcelen Y (2004). Factor XIII Val34Leu polymorphism does not contribute to the prevention of thrombotic complications in patients with antiphospholipid syndrome. Lupus, 13(1): 32–35

[14] Dossenbach-Glaninger A, van Trotsenburg M, Dossenbach M, Oberkanins C, Moritz A, Krugluger W, Huber J, Hopmeier P (2003). Plasminogen activator inhibitor 1 4G/5G polymorphism and coagulation factor XIII Val34Leu polymorphism: impaired fibrinolysis and early pregnancy loss. Clin Chem, 49(7): 1081–1086

[15] Elbaz A, Poirier O, Canaple S, Chédru F, Cambien F, Amarenco P (2000). The association between the Val34Leu polymorphism in the factor XIII gene and brain infarction. Blood, 95(2): 586–591

[16] Finan R R, Tamim H, Ameen G, Sharida H E, Rashid M, Almawi W Y (2002). Prevalence of factor V G1691A (factor V-Leiden) and prothrombin G20210A gene mutations in a recurrent miscarriage population. Am J Hematol, 71(4): 300–305

[17] Francis C W (2002). Factor XIII polymorphisms and venous thromboembolism. Arch Pathol Lab Med, 126(11): 1391–1393

[18] Franco R F, Reitsma P H, Lourenço D, Maffei F H, Morelli V, Tavella M H, Araújo A G, Piccinato C E, Zago M A (1999). Factor XIII Val34Leu is a genetic factor involved in the etiology of venous thrombosis. Thromb Haemost, 81(5): 676–679

[19] Goodman C S, Coulam C B, Jeyendran R S, Acosta V A, Roussev R (2006). Which thrombophilic gene mutations are risk factors for recurrent pregnancy loss? Am J Reprod Immunol, 56(4): 230–236

[20] Hancer V S, Diz-Kucukkaya R, Bilge A K, Ozben B, Oncul A, Ergen G, Nalcaci M (2006). The association between factor XIII Val34Leu polymorphism and early myocardial infarction. Circ J, 70(3): 239–242

[21] Hayano Y, Imai N, Karasawa T (1982) .Studies on the physiological changes of blood coagulation factor XIII during pregnancy and their significance (author's transl). Nihon Sanka Fujinka Gakkai Zasshi, 34(4): 469–477

[22] Jeddi-Tehrani M, Torabi R, Mohammadzadeh A, Arefi S, Keramatipour M, Zeraati H, Zarnani A H, Akhondi M M, Mahmoudian J, Mahmoudi A R, Zarei S (2010). Investigating association of three polymorphisms of coagulation factor XIII and recurrent pregnancy loss. Am J Reprod Immunol, 64(3): 212–217

[23] Kangsadalampai S, Board P G (1998). The Val34Leu polymorphism in the A subunit of coagulation factor XIII contributes to the large normal range in activity and demonstrates that the activation peptide plays a role in catalytic activity. Blood, 92(8): 2766–2770

[24] Khalid A S, Joyce C, O’Donoghue K (2013). Prevalence of subclinical and undiagnosed overt hypothyroidism in a pregnancy loss clinic. Ir Med J, 106(4): 107–110

[25] Kovalevsky G, Gracia C R, Berlin J A, Sammel M D, Barnhart K T (2004). Evaluation of the association between hereditary thrombophilias and recurrent pregnancy loss: a meta-analysis. Arch Intern Med, 164(5): 558–563

[26] López Ramírez Y, Vivenes M, Miller A, Pulido A, López Mora J, Arocha-Piñango C L, Marchi R (2006). Prevalence of the coagulation factor XIII polymorphism Val34Leu in women with recurrent miscarriage. Clin Chim Acta, 374(1-2): 69–74

[27] Madjunkova S, Volk M, Peterlin B, Plaseska-Karanfilska D (2012). Detection of thrombophilic mutations related to spontaneous abortions by a multiplex SNaPshot method. Genet Test Mol Biomarkers, 16(4): 259–264

[28] McCormack L J, Kain K, Catto A J, Kohler H P, Stickland M H, Grant P J (1998). Prevalence of FXIII V34L in populations with different cardiovascular risk. Thromb Haemost, 80(3): 523–524

[29] Mikkola H, Syrjälä M, Rasi V, Vahtera E, Hämäläinen E, Peltonen L, Palotie A (1994). Deficiency in the A-subunit of coagulation factor XIII: two novel point mutations demonstrate different effects on transcript levels. Blood, 84(2): 517–525

[30] Muszbek L, Bagoly Z, Bereczky Z, Katona E ( 2008). The involvement of blood coagulation factor XIII in fibrinolysis and thrombosis. Cardiovasc Hematol Agents Med Chem, 6(3):190–205

[31] Nelen W L, Blom H J, Steegers E A, den Heijer M, Eskes T K (2000). Hyperhomocysteinemia and recurrent early pregnancy loss: a meta-analysis. Fertil Steril, 74(6): 1196–1199

[32] Ozdemir O, Yenicesu G I, Silan F, Köksal B, Atik S, Ozen F, Göl M, Cetin A (2012). Recurrent pregnancy loss and its relation to combined parental thrombophilic gene mutations. Genet Test Mol Biomarkers, 16(4): 279–286

[33] Poursadegh Zonouzi A, Chaparzadeh N, Ghorbian S, Sadaghiani M M, Farzadi L, Ghasemzadeh A, Kafshdooz T, Sakhinia M, Sakhinia E (2013). The association between thrombophilic gene mutations and recurrent pregnancy loss. J Assist Reprod Genet, 30(10): 1353–1359

[34] Rallidis L S, Politou M, Komporozos C, Panagiotakos D B, Belessi C I, Travlou A, Lekakis J, Kremastinos D T (2008). Factor XIII Val34Leu polymorphism and the risk of myocardial infarction under the age of 36 years. Thromb Haemost, 99(6): 1085–1089

[35] Regan L, Rai R (2002). Thrombophilia and pregnancy loss. J Reprod Immunol, 55(1-2): 163–180

[36] Sajadi S, Samiei S, Kheirandish M, Jalaifar A(2008). The association of FXIII Val34Leu polymorphism with thrombotic events in patients referring to Iranian Blood Transfusion Organization. Sci J Iran Blood Transfus Organ, 4 (4): 247–252

[37] Suzuki K, Henke J, Iwata M, Henke L, Tsuji H, Fukunaga T, Ishimoto G, Szekelyi M, Ito S (1996). Novel polymorphisms and haplotypes in the human coagulation factor XIII A-subunit gene. Hum Genet, 98(4): 393–395

[38] Yioti G G, Panagiotou O A, Vartholomatos G A, Kolaitis N I, Pappa C N, Evangelou E, Stefaniotou M I (2013). Genetic polymorphisms associated with retinal vein occlusion: a Greek case-control study and meta-analysis. Ophthalmic Genet, 34(3): 130–139PMID:23289804

Acknowledgments

This work was financially supported by grant: (U-91011) from Vice-Chancellor for Research Affairs of Ahvaz Jundishapur University of Medical Sciences. We greatly appreciate the assistance provided by Dr. Zohre Sharifi of the coagulation center of Iranian blood transfusion organization. We also thank all the participants for their cooperation in the study.

Compliance with ethics guidelines

There is no conflict of interest.

RIGHTS & PERMISSIONS

2016 Higher Education Press and Springer-Verlag Berlin Heidelberg